Inventor · disambiguated record
Stéphane Dorich
Also filed as: DORICH STEPHANE · DORICH STÉPHANE
14 granted patents·10 pending applications·70 citations·filing 2021–2025
90Inventor score
Top patents by PatentIndex Score
24 records- 0197US11618751B1Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivativesVENTUS THERAPEUTICS U S INC·Filed 2022·Granted Apr 4, 2023·17 cites·5 claims
- 0295US12195460B2Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitorsVENTUS THERAPEUTICS U S INC·Filed 2024·Granted Jan 14, 2025·3 cites·6 claims
- 0394US12281112B2Compounds for inhibiting NLRP3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2024·Granted Apr 22, 2025·1 cites·18 claims
- 0492US12168657B2Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivativesVENTUS THERAPEUTICS U S INC·Filed 2022·Granted Dec 17, 2024·3 cites·9 claims
- 0592US11319319B1Compounds for inhibiting NLRP3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2021·Granted May 3, 2022·45 cites·20 claims
- 0690US12312350B2Compounds for inhibiting NLRP3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2024·Granted May 27, 2025·0 cites·9 claims
- 0788US12441728B2Pyridazine compounds for inhibiting NLRP3VENTUS THERAPEUTICS U S INC·Filed 2023·Granted Oct 14, 2025·0 cites·7 claims
- 0888US12398136B2Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitorsVENTUS THERAPEUTICS U S INC·Filed 2024·Granted Aug 26, 2025·0 cites·18 claims
- 0987US12312351B2Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitorsVENTUS THERAPEUTICS U S INC·Filed 2024·Granted May 27, 2025·0 cites·20 claims
- 1087US2025250270A1Compounds for inhibiting nlrp3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2024·Application pending·0 cites
- 1186US12410167B2Pyridazine compounds for inhibiting NLRP3VENTUS THERAPEUTICS U S INC·Filed 2023·Granted Sep 9, 2025·0 cites·17 claims
- 1285US2024158396A1Compounds for inhibiting nlrp3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2023·Application pending·0 cites
- 1383US12331048B2Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitorsVENTUS THERAPEUTICS U S INC·Filed 2023·Granted Jun 17, 2025·0 cites·18 claims
- 1483US2024409540A1PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORSVENTUS THERAPEUTICS U S INC·Filed 2024·Application pending·0 cites
- 1582US12116343B2Inhibitors of APOL1 and methods of using sameVERTEX PHARMA·Filed 2021·Granted Oct 15, 2024·1 cites·33 claims
- 1681US12351578B2Compounds for inhibiting NLRP3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2022·Granted Jul 8, 2025·0 cites·20 claims
- 1780US2025236620A1PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORSVENTUS THERAPEUTICS U S INC·Filed 2024·Application pending·0 cites
- 1877US2022340567A1Compounds for inhibiting nlrp3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2022·Application pending·0 cites
- 1965US2024368131A1Oxoindolinyl amide derivatives for inhibiting nlrp3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2024·Application pending·0 cites
- 2058US2025002487A1Heterocyclic compounds and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2022·Application pending·0 cites
- 2154US2024018138A1PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALSVENTUS THERAPEUTICS U S INC·Filed 2021·Application pending·0 cites
- 2254US2025257077A1BRIDGED BICYCLIC HETEROCYCLOALKYL PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORSVENTUS THERAPEUTICS U S INC·Filed 2025·Application pending·0 cites
- 2351US12264155B2Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitorsREPARE THERAPEUTICS INC·Filed 2021·Granted Apr 1, 2025·0 cites·23 claims
- 2444US2022185809A1Substituted 2-morpholinopyridine derivatives as atr kinase inhibitorsREPARE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stéphane Dorich files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →